No Data
With a compound annual growth rate of only 2.6% over the past five years, China's top 100 pharmaceutical companies are entering an adjustment period. How will the industry break through under internal and external pressures?
According to the data from China Meheco Group, in 2023, multiple operation indicators of the pharmaceutical industry's leading companies have declined. The compound annual growth rate of the top 100 pharmaceutical companies in the country in the past five years is only 2.6%, and the industry as a whole has entered the adjustment phase from the initial high-speed growth. Behind the weak growth, the health industry is also undergoing transformation: overseas licensing trades for innovative drugs have reached a new high, and leading companies are accelerating outward expansion...
Hansoh Pharma [03692] is now trading at 18.5 Hong Kong dollars, a decrease of 6.94%.
As of 11:47, Hansoh Pharma [03692] reported a price of 18.5 Hong Kong dollars, a decrease of 1.38 Hong Kong dollars or 6.94% from yesterday's closing price of 19.88 Hong Kong dollars. The trading volume was 75.8238 million Hong Kong dollars. The highest price today was 20.15 Hong Kong dollars, and the lowest price was 18.48 Hong Kong dollars. Based on yesterday's closing price, the 10-day average price was 17.61 Hong Kong dollars and the 50-day average price was 16.44 Hong Kong dollars. The current PE ratio is 27.75 times and the 14-day relative strength index is 33.33.
Founder Securities: the revenue growth rate of the pharmacy sector slows down, and the concentration is expected to accelerate.
The individual account reform of medical insurance has led to a decrease in personal account income, affecting pharmaceutical sales and pharmacy business relying on individual account payments. In 2023, pharmacy medical insurance personal account expenditures decreased by 9%, and this trend is expected to continue in 2024.
Is the chain of pharmacies entering a "mini ice age"? H1 growth rate "downgrades", the industry's high-growth stores may reach turning point.
① The growth rate of sales revenue of all categories in retail pharmacies has slowed down, and the competition in stock continues to intensify. In the first half of this year, it was difficult for major chain pharmacies to increase revenue and profit. ② In the future, the focus of pharmacy competition will shift to commodity extension and services. According to the prediction of Zhongkang Industry Research Institute, the growth rate of pharmaceuticals in all end terminals in 2024 is expected to decrease to 4.9%, a decrease from 2023.
Will you be eliminated if you don't go overseas? In the first half of the year, the proportion of innovative drug outbound business development accounted for about 80% | Industry Dynamics.
①At the 2024 New Investment Conference hosted by Frost Sullivan, the issue of going global was favored by participants. ②There is a new trend in the export of innovative drugs in China, for example, the number of export BDs exceeded License-in for the first time in 2023. ③Some participating experts put forward rational opinions and called for internal strength, not just enthusiasm.
HK$22.04 - That's What Analysts Think Hansoh Pharmaceutical Group Company Limited (HKG:3692) Is Worth After These Results
No Data
No Data
